Haleon plc (HLN)
| Market Cap | 43.75B +7.7% |
| Revenue (ttm) | 14.80B +1.2% |
| Net Income | 2.15B +6.6% |
| EPS | 0.48 +8.5% |
| Shares Out | 8.89B |
| PE Ratio | 20.69 |
| Forward PE | 17.40 |
| Dividend | $0.19 (1.89%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 18,334,699 |
| Open | 9.97 |
| Previous Close | 9.68 |
| Day's Range | 9.91 - 10.06 |
| 52-Week Range | 8.65 - 11.28 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 11.93 (+20.02%) |
| Earnings Date | Jul 30, 2026 |
About HLN
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal dr... [Read more]
Financial Performance
In 2025, Haleon's revenue was 11.03 billion, a decrease of -1.81% compared to the previous year's 11.23 billion. Earnings were 1.67 billion, an increase of 15.60%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for HLN stock is "Buy." The 12-month stock price target is $11.93, which is an increase of 20.02% from the latest price.
News
Only Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore
Nostalgia-fueled experience introduces Excedrin Rapid Relief, providing fast relief of tough pain that starts in as little as 15 minutes Key Takeaways: Excedrin is introducing My Little Headache, a no...
Pre-Market Most Active for Oct 8, 2026 : AIXI, SQQQ, TQQQ, IBIT, APLD, INTC, NOK, STLA, HLN, WOLF, IONQ, BABA
The NASDAQ 100 Pre-Market Indicator is down -198.93 to 30,961.15. The total Pre-Market volume is currently 120,264,182 shares traded.The following are the most active stocks for the pre-market session...
Haleon price target lowered to 295 GBp from 315 GBp at JPMorgan
JPMorgan lowered the firm’s price target on Haleon (HLN) to 295 GBp from 315 GBp and keeps an Underweight rating on the shares.
JPMorgan Lowers Haleon (HLN) Price Target Amid Dividend Sustainability Concerns
JPMorgan Lowers Haleon (HLN) Price Target Amid Dividend Sustainability Concerns
JPMorgan cuts Haleon target, places on ‘Negative Catalyst Watch’
JPMorgan lowered the firm’s price target on Haleon (HLN) to 295 GBp from 315 GBp and keeps an Underweight rating on the shares. JPMorgan also placed Haleon on “Negative Catalyst…
Pre-Market Most Active for Sep 23, 2026 : IONQ, GRAB, SQQQ, TQQQ, GLND, NOK, NVDA, INTC, BMNR, BABA, HLN, BB
The NASDAQ 100 Pre-Market Indicator is down -90.2 to 30,642.2. The total Pre-Market volume is currently 102,035,158 shares traded.The following are the most active stocks for the pre-market session: I...
Haleon price target lowered to 400 GBp from 410 GBp at Jefferies
Jefferies analyst David Hayes lowered the firm’s price target on Haleon (HLN) to 400 GBp from 410 GBp and keeps a Buy rating on the shares as part of a…
Maidenhead toothpaste factory demolition plan gets go-ahead
A plan to demolish a former toothpaste and mouthwash factory and replace it with three smaller industrial units has been approved. The site in Norreys Drive, Maidenhead, waspreviously used by Haleon, ...
HLN Looks 8.3% Undervalued on GF Value™ as Dividend Remains Attractive
HLN Looks 8.3% Undervalued on GF Value™ as Dividend Remains Attractive
Advil-maker Haleon boosts sales by targeting consumers on weight-loss drugs
Advil maker Haleon is capitalizing on the GLP-1 boom, boosting sales of products that combat weight loss drugs side effects with strategic store placement.
Advil-maker Haleon boosts US sales by targeting consumers on weight-loss drugs
Consumer health company Haleon has achieved growing sales of products to counter side-effects of weight-loss drugs in the United States, the company said, capitalising on the rising popularity of GL...
Haleon price target lowered to 320 GBp from 335 GBp at Deutsche Bank
Deutsche Bank analyst Tom Sykes lowered the firm’s price target on Haleon (HLN) to 320 GBp from 335 GBp and keeps a Sell rating on the shares. Published first on…
Haleon secures better shelf space at Walmart, Target in bid to boost market share
Sensodyne toothpaste maker Haleon has quietly negotiated better spots on shelves at U.S. retailers including Walmart and Target , to gain more visibility at a at a time when mounting grocery bills ar...
Haleon price target raised to 410 GBp from 400 GBp at Jefferies
Jefferies raised the firm’s price target on Haleon (HLN) to 410 GBp from 400 GBp and keeps a Buy rating on the shares. The company reported a “cleaner Q2 than…
Haleon Completes Tender Offer For 2027 Notes, Sets Settlement For August 21
(RTTNews) - Haleon plc (HLN), a consumer health company, announced the pricing terms, expiration, and results of its cash tender offer for its outstanding $1.999 billion 3.375% Fixed Rate Senior Notes...
Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes
LONDON, Aug. 19, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the pricing terms, expiration and results of the offer to buy back any and all of the outst...
Haleon price target raised to 390 GBp from 370 GBp at RBC Capital
RBC Capital raised the firm’s price target on Haleon (HLN) to 390 GBp from 370 GBp and keeps a Sector Perform rating on the shares.
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes
LONDON, Aug. 11, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy ...
Haleon price target raised to 460 GBp from 430 GBp at Morgan Stanley
Morgan Stanley raised the firm’s price target on Haleon (HLN) to 460 GBp from 430 GBp and keeps an Overweight rating on the shares.
ACCO vs. HLN: Which Stock Is the Better Value Option?
ACCO vs. HLN: Which Stock Is the Better Value Option?
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
Haleon H1 Earnings Call Highlights
Haleon NYSE: HLN said its second-quarter organic sales growth accelerated to 3.1% from 2.2% in the first quarter, supported by improved execution in North America, continued growth in emerging markets...
Haleon Earnings Call Transcript: H1 2026
Q2 organic sales grew 3.1% with margin and EPS improvements, led by North America, China, and Latin America. Outlook remains confident for 3%-5% full-year growth, with H2 expected to benefit from emerging markets, cold and flu recovery, and continued innovation.
Haleon Quarterly report: H1 2026
Haleon has published its H1 2026 quarterly earnings report on July 30, 2026.
Haleon Slides: H1 2026
Haleon has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.